Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Most rhesus macaques infected with the CCR5-tropic SHIV(AD8) generate cross-reactive antibodies that neutralize multiple HIV-1 strains.

Shingai M, Donau OK, Schmidt SD, Gautam R, Plishka RJ, Buckler-White A, Sadjadpour R, Lee WR, LaBranche CC, Montefiori DC, Mascola JR, Nishimura Y, Martin MA.

Proc Natl Acad Sci U S A. 2012 Nov 27;109(48):19769-74. doi: 10.1073/pnas.1217443109. Epub 2012 Nov 5.

2.

Pathogenicity and mucosal transmissibility of the R5-tropic simian/human immunodeficiency virus SHIV(AD8) in rhesus macaques: implications for use in vaccine studies.

Gautam R, Nishimura Y, Lee WR, Donau O, Buckler-White A, Shingai M, Sadjadpour R, Schmidt SD, LaBranche CC, Keele BF, Montefiori D, Mascola JR, Martin MA.

J Virol. 2012 Aug;86(16):8516-26. doi: 10.1128/JVI.00644-12. Epub 2012 May 30.

3.

Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques.

Cho MW, Kim YB, Lee MK, Gupta KC, Ross W, Plishka R, Buckler-White A, Igarashi T, Theodore T, Byrum R, Kemp C, Montefiori DC, Martin MA.

J Virol. 2001 Mar;75(5):2224-34.

4.
5.

Development of a tier 1 R5 clade C simian-human immunodeficiency virus as a tool to test neutralizing antibody-based immunoprophylaxis.

Siddappa NB, Hemashettar G, Wong YL, Lakhashe S, Rasmussen RA, Watkins JD, Novembre FJ, Villinger F, Else JG, Montefiori DC, Ruprecht RM.

J Med Primatol. 2011 Apr;40(2):120-8. doi: 10.1111/j.1600-0684.2010.00454.x. Epub 2010 Nov 2.

6.

In vitro neutralization of low dose inocula at physiological concentrations of a monoclonal antibody which protects macaques against SHIV challenge.

Davis D, Koornstra W, Fagrouch Z, Verschoor EJ, Heeney JL, Bogers WM.

PLoS One. 2013 Aug 16;8(8):e72702. doi: 10.1371/journal.pone.0072702. eCollection 2013.

7.

Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose.

Sholukh AM, Byrareddy SN, Shanmuganathan V, Hemashettar G, Lakhashe SK, Rasmussen RA, Watkins JD, Vyas HK, Thorat S, Brandstoetter T, Mukhtar MM, Yoon JK, Novembre FJ, Villinger F, Landucci G, Forthal DN, Ratcliffe S, Tuero I, Robert-Guroff M, Polonis VR, Bilska M, Montefiori DC, Johnson WE, Ertl HC, Ruprecht RM.

Retrovirology. 2014 Jan 20;11:8. doi: 10.1186/1742-4690-11-8.

8.

Mucosal transmissibility, disease induction and coreceptor switching of R5 SHIVSF162P3N molecular clones in rhesus macaques.

Ren W, Mumbauer A, Zhuang K, Harbison C, Knight H, Westmoreland S, Gettie A, Blanchard J, Cheng-Mayer C.

Retrovirology. 2013 Jan 31;10:9. doi: 10.1186/1742-4690-10-9.

9.

AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges.

Gardner MR, Kattenhorn LM, Kondur HR, von Schaewen M, Dorfman T, Chiang JJ, Haworth KG, Decker JM, Alpert MD, Bailey CC, Neale ES Jr, Fellinger CH, Joshi VR, Fuchs SP, Martinez-Navio JM, Quinlan BD, Yao AY, Mouquet H, Gorman J, Zhang B, Poignard P, Nussenzweig MC, Burton DR, Kwong PD, Piatak M Jr, Lifson JD, Gao G, Desrosiers RC, Evans DT, Hahn BH, Ploss A, Cannon PM, Seaman MS, Farzan M.

Nature. 2015 Mar 5;519(7541):87-91. doi: 10.1038/nature14264. Epub 2015 Feb 18.

10.

Importance of the V1/V2 loop region of simian-human immunodeficiency virus envelope glycoprotein gp120 in determining the strain specificity of the neutralizing antibody response.

Laird ME, Igarashi T, Martin MA, Desrosiers RC.

J Virol. 2008 Nov;82(22):11054-65. doi: 10.1128/JVI.01341-08. Epub 2008 Sep 3. Erratum in: J Virol. 2009 Feb;83(4):2055.

11.

Pathogenic infection of Macaca nemestrina with a CCR5-tropic subtype-C simian-human immunodeficiency virus.

Ho O, Larsen K, Polacino P, Li Y, Anderson D, Song R, Ruprecht RM, Hu SL.

Retrovirology. 2009 Jul 14;6:65. doi: 10.1186/1742-4690-6-65.

12.

R5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect env evolution and to develop AIDS vaccines in primate models.

Siddappa NB, Watkins JD, Wassermann KJ, Song R, Wang W, Kramer VG, Lakhashe S, Santosuosso M, Poznansky MC, Novembre FJ, Villinger F, Else JG, Montefiori DC, Rasmussen RA, Ruprecht RM.

PLoS One. 2010 Jul 21;5(7):e11689. doi: 10.1371/journal.pone.0011689.

13.
14.

Characterization and Implementation of a Diverse Simian Immunodeficiency Virus SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multimodal Vaccines Expressing the SIVmac239 Envelope.

Kilgore KM, Murphy MK, Burton SL, Wetzel KS, Smith SA, Xiao P, Reddy S, Francella N, Sodora DL, Silvestri G, Cole KS, Villinger F, Robinson JE, Pulendran B, Hunter E, Collman RG, Amara RR, Derdeyn CA.

J Virol. 2015 Aug;89(16):8130-51. doi: 10.1128/JVI.01221-14. Epub 2015 May 27.

15.

Construction and characterization of a new simian/human immunodeficiency viruses clone carrying an env gene derived from a CRF07_BC strain.

Li Y, Yang GB, Chen QM, Liu Q, Meng ZF, Geng YQ, Qiao WT, Shao YM.

Chin Med J (Engl). 2009 Dec 5;122(23):2874-9.

PMID:
20092794
16.

Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies.

Kraft Z, Derby NR, McCaffrey RA, Niec R, Blay WM, Haigwood NL, Moysi E, Saunders CJ, Wrin T, Petropoulos CJ, McElrath MJ, Stamatatos L.

J Virol. 2007 Jun;81(12):6402-11. Epub 2007 Mar 28.

17.

SHIV-1157i and passaged progeny viruses encoding R5 HIV-1 clade C env cause AIDS in rhesus monkeys.

Humbert M, Rasmussen RA, Song R, Ong H, Sharma P, Chenine AL, Kramer VG, Siddappa NB, Xu W, Else JG, Novembre FJ, Strobert E, O'Neil SP, Ruprecht RM.

Retrovirology. 2008 Oct 17;5:94. doi: 10.1186/1742-4690-5-94.

18.

Protection against mucosal SIVsm challenge in macaques infected with a chimeric SIV that expresses HIV type 1 envelope.

Quesada-Rolander M, Mäkitalo B, Thorstensson R, Zhang YJ, Castaños-Velez E, Biberfeld G, Putkonen P.

AIDS Res Hum Retroviruses. 1996 Jul 20;12(11):993-9.

PMID:
8827215
20.

Immunization with wild-type or CD4-binding-defective HIV-1 Env trimers reduces viremia equivalently following heterologous challenge with simian-human immunodeficiency virus.

Sundling C, O'Dell S, Douagi I, Forsell MN, Mörner A, Loré K, Mascola JR, Wyatt RT, Karlsson Hedestam GB.

J Virol. 2010 Sep;84(18):9086-95. doi: 10.1128/JVI.01015-10. Epub 2010 Jul 7.

Supplemental Content

Support Center